Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Montelukast 10 mg Film-coated Tablets is a leukotriene receptor antagonist that blocks the substance called leukotrienes. Leukotrienes can cause the narrowing and swelling of airways in your lungs and also cause allergy symptoms. By blocking leukotrienes, this medicine improves asthma symptoms, helps control asthma and improves seasonal allergy symptoms (also known as hay fever or seasonal allergic rhinitis).
Your doctor has prescribed Montelukast 10 mg Film-coated Tablets to treat asthma, preventing your asthma symptoms during the day and night.
• This medicine is used for the treatment of adults and adolescents 15 years of age and older who are not adequately controlled on their medication and need additional therapy.
• This medicine also helps prevent the narrowing of airways triggered by exercise.
• In those asthmatic patients in whom this medicine is indicated in asthma, this medicine can also provide symptomatic relief of seasonal allergic rhinitis.
Your doctor will determine how this medicine should be used depending on the symptoms and severity of your asthma.
What is asthma? Asthma is a long-term disease.
Asthma includes:
• Difficulty in breathing because of the narrowed airways. This narrowing of airways worsens and improves in response to various conditions.
• Sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.
• Swelling (inflammation) in the lining of the airways.
Symptoms of asthma include: coughing, wheezing, and chest tightness.
What are seasonal allergies? Seasonal allergies (also known as hay fever or seasonal allergic rhinitis) are an allergic response often caused by airborne pollen from trees, grass and weeds. The symptoms of seasonal allergies typically may include stuffy, runny, itchy nose; sneezing; watery, swollen, red and itchy eyes.
Tell your doctor about any medical problems or allergies you have now or previously had.
Do not take Montelukast 10 mg Film-coated Tablets If you are allergic to montelukast or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions Talk to your doctor or pharmacist before taking this medicine.
• If your asthma or breathing gets worse, tell your doctor immediately.
• Oral Montelukast 10 mg Film-coated Tablets is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you. Always have with you, your inhaled rescue medicine for asthma attack.
• Any patient on anti-asthma medicines should be aware that if you develop a combination of symptoms such as a flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.
• You should not take acetyl-salicyclic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti--inflammatory drugs or NSAIDS) if they make your asthma worse.
• It is important that you or your child takes all asthma medicines as prescribed by your doctor.
Montelukast should not be used in place of other asthma medications your doctor has prescribed for you.
Various neuropsychiatric events (for example behaviour and mood-related changes, depression and suicidality) have been reported in patients of all ages treated with montelukast (see section 4). There have also been reports of these symptoms continuing after treatment is stopped. If you develop such symptoms while taking montelukast or if these symptoms do not resolve after montelukast is stopped, you should contact your prescriber.
Children and Adolescents Do not give this medicine to children less than 15 years of age.
For children from the age of 2 to 5 years old, Montelukast 4 mg Chewable Tablets are available.
For children from the age of 6 to 14 years old, Montelukast 5 mg Chewable Tablets are available.
For children 6 months to 5 years 4mg granules are also available.
Other medicines and Montelukast 10 mg Film-coated Tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those medicines obtained without a prescription. This includes medicines, herbal remedies, health products or supplements that you have obtained without a prescription.
Treatment with Montelukast 10 mg Film-coated Tablets can be affected by other medicines. Some medicines may affect how montelukast works, or montelukast may affect how other medicines work.
Tell your doctor if you are taking any of the following medicines before starting Montelukast 10 mg
Film-coated Tablets:
Phenobarbital (used for treatment of epilepsy)
Phenytoin (used for treatment of epilepsy)
Rifampicin (used to treat tuberculosis and some other infections)
Gemfibrozil (used for treatment of high lipid levels in plasma).
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine.
Pregnancy
Women who are pregnant or intend to become pregnant should consult their doctor before taking this medicine. Your doctor will assess whether you can take this medicine during this time.
Breast-feeding
It is not known if this medicine appears in breast milk. You should consult your doctor before taking this medicine if you are breast feeding or intend to breast-feed.
Driving and using machines This medicine is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with this medicine may affect some patients ability to drive or operate machinery, therefore caution is advised.
Montelukast 10 mg Film-coated Tablets contains lactose This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars (rare hereditary problems, galactose intolerance, the lapp lactose deficiency of glucose-galactose malabsorption), you should contact your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
• You should take only one tablet of this medicine once a day as prescribed by your doctor.
• It should be taken even when you have no symptoms or have an acute asthma attack.
• To be taken by mouth.
For adults and adolescents aged 15 years and older The recommended dose is one 10 mg tablet to be taken daily in the evening. This medicine may be taken with or without food.
If you are taking this medicine, be sure that you do not take any other products that contain the same active ingredient, montelukast.
If you take more Montelukast 10 mg Film-coated Tablets than you should If you take more tablets than you should contact your doctor immediately for advice.
There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and adolescents included abdominal pain, sleepiness, thirst, headache, vomiting and hyperactivity (unusually active).
If you forget to take Montelukast 10 mg Film-coated Tablets Try to take this medicine as recommended to you by your doctor. However, if you miss a dose, just take your tablet as soon as you remember. Take your next dose of one tablet once daily at the usual time. Do not take a double dose to make up for a forgotten tablet.
If you stop taking Montelukast 10 mg Film-coated Tablets This medicine can treat your asthma only if you continue to take it. It is important to continue taking this medicine as prescribed to you by your doctor. It will help control your asthma.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In clinical studies with Montelukast 10 mg film-coated tablets, the most commonly reported side effects (may affect up to 1 in 10 people) thought to be related to this medicine were:
• Abdominal pain
• Headache
These were usually mild and occurred at a greater frequency in patients treated with montelukast than placebo (a pill containing no medication).
Serious side effects
Talk with your doctor immediately if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment.
Uncommon: the following may affect up to 1 in 100 people
• allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing
• behaviour and mood related changes: agitation including aggressive behaviour or hostility, depression
• seizure
Rare: the following may affect up to 1 in 1,000 people
• increased bleeding tendency
• tremor
• palpitations
Very rare: the following may affect up to 1 in 10,000 people
• combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) (see section 2)
• low blood platelet count
• behaviour and mood related changes: hallucinations, disorientation, suicidal thoughts and actions
• swelling (inflammation) of the lungs
• severe skin reactions (erythema multiforme) that may occur without warning
• inflammation of the liver (hepatitis)
Additionally, while the medicine has been on the market, the following have been reported:
Very common side effects (may affect more than 1 in 10 people):
• upper respiratory infection
Common side effects (may affect up to 1 in 10 people):
• diarrhoea
• nausea
• vomiting
• rash
• elevated liver enzymes
• fever
Uncommon side effects (may affect up to 1 in 100 people):
• nose bleed
• dry mouth
• indigestion
• bruising
• itching
• hives
• joint and / or muscle pain, muscle cramps
• bedwetting in children
• pins and needles/ numbness
• weakness/ tiredness
• feeling unwell
• swelling
• feeling dizzy
• feeling drowsy
Behaviour and mood related changes, such as:
• dream abnormalities
• nightmares
• trouble sleeping
• sleep walking
• irritability
• feeling anxious
• restlessness
Rare side effects (may affect up to than 1 in 1,000 people):
• behaviour and mood related changes: disturbance in attention, memory impairment, uncontrolled muscle movements
Very rare side effects (may affect up to 1 in 10,000 people):
• tender red lumps under the skin, most commonly on your shins (erythema nodosum)
• behaviour and mood related changes: obsessive-compulsive symptoms, stuttering
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
HDPE container:
Use within 30 days of opening. Once the pack has been opened write the date of opening on the space provided on the package label and also write the date by when the product should be used.
Store the medicine in the original package to protect from moisture. This medicinal product does not require any special temperature storage conditions.
Aluminium/aluminium blisters:
Store in the original package to protect from moisture. Do not store above 30ºC.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Montelukast 10 mg Film-coated Tablets contains • The active substance is montelukast sodium. Each tablet contains montelukast sodium which corresponds to 10 mg of montelukast.
• The other ingredients are:
Core:
Cellulose microcrystalline
Lactose monohydrate
Croscarmellose sodium
Hydroxypropylcellulose (E463)
Magnesium stearate
Film-coating:
Hypromellose (E464)
Hydroxypropylcellulose (E463)
Titanium dioxide (E171)
Iron Oxide yellow (E172)
Carnauba wax (E903)
Iron Oxide red (E172)
What Montelukast 10 mg Film-coated Tablets looks like and contents of the pack 10 mg tablets are beige, round, 8 mm biconvex, film-coated tablets, engraved with 'G' on one side and '392'on the other side.
Montelukast 10 mg Film-coated Tablets are available in Aluminium/Aluminium blister pack or HDPE containers in cardboard carton with polypropylene child resistant closure and silica gel desiccant canister.
Pack sizes: 20, 28, 30, 50 and 100.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder
Glenmark Pharmaceuticals Europe Limited
Laxmi House
2-B Draycott Avenue
Kenton
Harrow
Middlesex
HA3 0BU
United Kingdom
Manufacturer
Glenmark Pharmaceuticals s.r.o.
City Tower
Hvězdova 1716/2b
140 78 Prague 4
Czech Republic
Glenmark Pharmaceuticals Europe Limited
Building 2
Croxley Green Business Park
Croxley Green
Hertfordshire
WD18 8YA
United Kingdom
This leaflet was last revised in 06/2026.
V 3.0
PL 25258/0010 – UK National procedure
Type IB Update SmPC and PIL as per MHRA request
June 2026
Glenmark Pharmaceuticals Europe Ltd
Address
Building 2, Croxley Park, Watford, WD18 8YA
Telephone
+44 (0)1923 202 950
Fax
+44 (0)1923 251137
Medical Information Direct Line
0800 458 0383
E-mail
[email protected]
Stock Availability
+44 (0)1923 202 950
WWW
www.glenmarkpharma.com
• Contact us
• Links
• Accessibility
• Legal and privacy notice
• Cookie notice
• Cookie Settings
• Glossary
• Site Maps
Delivered to you by
Montelukast 10 mg Film-coated Tablets comes as tablet containing 10mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Montelukast 10 mg Film-coated Tablets is montelukast sodium.
Medicines with the same active substance, strength and form include: Singulair 10 mg film-coated tablets, Montelukast 10 mg film-coated tablets, Montelukast 10 mg film-coated tablets. In total there are 6 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Montelukast 10 mg Film-coated Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Montelukast is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting β-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Montelukast is indicated in asthma, Montelukast can also provide symptomatic relief of seasonal allergic rhinitis.
Montelukast is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.
Posology
The recommended dose for adults and adolescents 15 years of age and older with asthma, or with asthma and concomitant seasonal allergic rhinitis, is one 10-mg tablet daily to be taken in the evening.
General recommendations
The therapeutic effect of Montelukast on parameters of asthma control occurs within one day.
Montelukast may be taken with or without food. Patients should be advised to continue taking Montelukast even if their asthma is under control, as well as during periods of worsening asthma.
Montelukast should not be used concomitantly with other products containing the same active ingredient, montelukast.
No dosage adjustment is necessary for the elderly, or for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.
PaediatricPopulation
Do not give Montelukast 10mg film coated tablets to children less than 15 years of age. The safety and efficacy of Montelukast 10mg film coated tablets in children less than 15 years has not been established.
Montelukast 5 mg Chewable Tablets are available for paediatric patients 6 to 14 years of age.
Montelukast 4 mg Chewable Tablets are available for paediatric patients 2 to 5 years of age.
There are different form(s) of this medicine available for paediatric patients based on age range, for children who have problems consuming a chewable tablet.
Therapy with Montelukast in relation to other treatments for asthma
Montelukast can be added to a patient's existing treatment regimen.
Inhaled corticosteroids
Treatment with Montelukast can be used as add-on therapy in patients when inhaled corticosteroids plus "as needed" short acting β-agonists provide inadequate clinical control. Montelukast should not be abruptly substituted for inhaled corticosteroids (see section 4.4).
Method of administration:
For oral use. The tablet should be swallowed with a sufficient amount of water.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Neuropsychiatric events such as behavioural changes, depression and suicidality have been reported in all age groups taking montelukast (see section 4.8). The symptoms may be serious and continue if the treatment is not withdrawn. Therefore the treatment with montelukast should be discontinued if neuropsychiatric symptoms occur during treatment.
Advise patients and/or caregivers to be alert for neuropsychiatric events and instruct them to notify their physician if these changes in behaviour occur.
There have been post-marketing reports which indicate that some neuropsychiatric symptoms may persist after montelukast is stopped. Advise patients and/or caregivers to be remain vigilant for symptoms that do not resolve following discontinuation of montelukast and to notify their prescriber accordingly.
Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled β-agonist should be used. Patients should seek their doctors' advice as soon as possible if they need more inhalations of short-acting β-agonists than usual.
Montelukast should not be substituted abruptly for inhaled or oral corticosteroids.
There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.
In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy (see section 4.8). These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.
Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.
This medicinal product contains lactose (monohydrate).
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.
This medicinal product is essentially sodium free.
Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/ norethindrone 35/1), terfenadine, digoxin and warfarin.
The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.
In vitro studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolized by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 in vivo. Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).
In vitro studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.
Based on in vitro data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.
Pregnancy
Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.
Available data from published prospective and retrospective cohort studies with montelukast use in pregnant women evaluating major birth defects have not established a drug-associated risk. Available studies have methodologic limitations, including small sample size, in some cases retrospective data collection, and inconsistent comparator groups.
Montelukast may be used during pregnancy only if it is considered to be clearly essential.
Breast-feeding
Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is not known if montelukast/metabolites are excreted in human milk.
Montelukast may be used in breast-feeding only if it is considered to be clearly essential.
Montelukast has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness
Montelukast has been evaluated in clinical studies as follows:
• 10-mg film-coated tablets in approximately 4,000 adult and adolescent asthmatic patients 15 years of age and older.
• 10-mg film-coated tablets in approximately 400 adult and adolescent asthmatic patients with seasonal allergic rhinitis 15 years of age and older.
• 5-mg chewable tablets in approximately 1,750 paediatric asthmatic patients 6 to 14 years of age.
The following drug-related adverse reactions in clinical studies were reported commonly (≥1/100 to <1/10) in asthmatic patients treated with montelukast and at a greater incidence than in patients treated with placebo:
Body System Class
Adult and Adolescent Patients 15 years and older
(two 12-week studies; n=795)
Paediatric Patients 6 to 14 years old
(one 8-week study; n=201)
(two 56-week studies; n=615)
Nervous system disorders
headache
headache
Gastro-intestinal disorders
abdominal pain
With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.
Tabulated list of Adverse Reactions
Adverse reactions reported in post-marketing use and clinical experience are listed, by MedDRA System Organ Class and ranked by frequency as follows:
Very Common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1000 to <1/100), Rare (≥1/10,000 to <1/1000), Very Rare (≥1/10,000) and Not known (cannot be estimated from the available data)
System Organ Class
Adverse Experience Term
Frequency Category*
Infections and infestations
upper respiratory infection†
Very Common
Blood and lymphatic system disorders
increased bleeding tendency
Rare
thrombocytopenia
Very Rare
Immune system disorder
hypersensitivity reactions including anaphylaxis
Uncommon
hepatic eosinophilic infiltration
Very Rare
Psychiatric disorders
dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor§)
Uncommon
disturbance in attention, memory impairment, tic
Rare
hallucinations, disorientation, suicidal thinking and behaviour (suicidality), obsessive-compulsive symptoms, dysphemia
Very Rare
Nervous system disorder
dizziness, drowsiness paraesthesia/hypoesthesia, seizure
Uncommon
Cardiac disorders
palpitations
Rare
Respiratory, thoracic and mediastinal disorders
epistaxis
Uncommon
Churg‑Strauss Syndrome (CSS) (see section 4.4)
Very Rare
pulmonary eosinophilia
Very Rare
Gastrointestinal disorders
diarrhoea‡, nausea‡, vomiting‡
Common
dry mouth, dyspepsia
Uncommon
Hepatobiliary disorders
elevated levels of serum transaminases (ALT, AST)
Common
hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).
Very Rare
Skin and subcutaneous tissue disorders
rash‡
Common
bruising, urticaria, pruritus
Uncommon
angiooedema
Rare
erythema nodosum, erythema multiforme
Very Rare
Musculoskeletal and connective tissue disorders
arthralgia, myalgia including muscle cramps
Uncommon
Renal and urinary disorders
Enuresis in children
Uncommon
General disorders and administration site conditions
pyrexia‡
Common
asthenia/fatigue, malaise, oedema,
Uncommon
†This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.
‡This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.
§ Frequency Category: Rare
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.
In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.
There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports.
Symptoms of overdose
The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.
Management of overdose
No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal or haemodialysis.
Ask anything about Montelukast 10 mg Film-coated Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.